Skip to main content

Advertisement

SpringerLink
Log in

Characterizing risk factors for hospitalization for psoriasis patients

  • ORIGINAL PAPER
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic autoimmune disease with a large economic impact. Inpatient care is a significant expense, and about one-third of patients admitted for psoriasis are readmitted. Reducing hospitalizations and readmissions is an important goal for improving outcomes for psoriasis patients. The objective of this study is to characterize patients who are hospitalized for psoriasis, and differentiate features for patients with a single hospitalization from those who were hospitalized multiple times during the study period. Hospitalized psoriasis patients were identified from an in-patient database at a single academic institution. Differences between psoriasis patients with one hospitalization and those with multiple hospitalizations were characterized, as were differences between patients who were hospitalized primarily for psoriasis and those who were admitted primarily for other reasons. Patients who were primarily hospitalized for psoriasis had fewer comorbidities, shorter hospitalizations, and a lower death rate than those hospitalized for other reasons. Patients with multiple hospitalizations had more comorbidities and worse outcomes than patients with a single hospitalization. Patients who are hospitalized primarily for psoriasis are more likely to be pustular, and tend to have fewer comorbidities and better outcomes than patients with psoriasis who are hospitalized with psoriasis as a secondary diagnosis. One limitation of this study is the lack of data available to consistently quantify disease severity, such as percent of body surface area affected by psoriasis or Physician’s Global Assessment score.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Nowowiejska J, Baran A, Flisiak I (2020) Psoriasis and cardiometabolic disorders. Dermatol Rev/Przegląd Dermatologiczny 107(6):508–520

    Google Scholar 

  2. Asgari MM, Wu JJ, Gelfand JM, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf [Internet]. 2013 Aug [cited 2020 Oct 17];22(8):842–9. Available from: /pmc/articles/PMC3720770/?report=abstract

  3. Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis Data From National Psoriasis Foundation Survey Panels [Internet]. Vol. 149, JAMA Dermatol. 2013. https://jamanetwork.com/

  4. Cheng BT, Silverberg JI (2020) Predictors of hospital readmission in United States adults with psoriasis. J Am Acad Dermatol 82(4):902–909

    Article  PubMed  Google Scholar 

  5. Dalgard FJ, Gieler U, Tomas-Aragones L et al (2015) The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 135(4):984–991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Eppinga H, Poortinga S, Thio HB, et al. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. Inflamm Bowel Dis [Internet]. 2017 Oct 1 [cited 2020 Jul 21];23(10):1783–9. https://academic.oup.com/ibdjournal/article/23/10/1783-1789/4791654

  7. Kimball A, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatology Venereol [Internet]. 2011 Feb 1 [cited 2020 Jul 24];25(2):157–63. http://doi.wiley.com/https://doi.org/10.1111/j.1468-3083.2010.03730.x

  8. Menter A, Strober BE, Kaplan DH et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029–1072

    Article  PubMed  Google Scholar 

  9. Mw D, Hajdarbegovic BE. Psoriasis: Targets and Therapy Dovepress Drug-induced psoriasis: clinical perspectives. Psoriasis Targets Ther [Internet]. 2017 [cited 2020 Oct 11];7–87. Available from: http://dx.doi.org/https://doi.org/10.2147/PTT.S126727

  10. Pustular psoriasis: Management - UpToDate [Internet]. [cited 2020 Aug 26]. https://www.uptodate.com/contents/pustular-psoriasis-management?search=psoriasis treatment&topicRef=5666&source=see_link#H167785525

  11. Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512–516

    Article  PubMed  Google Scholar 

  12. Vanderpuye-Orgle J, Zhao Y, Lu J et al (2015) Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 72(6):961-967.e5

    Article  PubMed  Google Scholar 

  13. Zhang M, Markova A, Harp J, et al. Dermatology-specific and all-cause 30-day and calendar-year readmissions and costs for dermatologic diseases from 2010 to 2014. J Am Acad Dermatol [Internet]. 2019 Sep 1 [cited 2020 Dec 13];81(3):740–8. https://pubmed.ncbi.nlm.nih.gov/31102603/

  14. Buster KJ, Stevens EI, Elmets CA (2012) Dermatologic health disparities. Dermatol Clin 30(1):53–59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chen CL, Fitzpatrick L, Kamel H (2014) Who uses the emergency department for dermatologic care? A statewide analysis. J Am Acad Dermatol 71(2):308–313

    Article  PubMed  Google Scholar 

  16. Gilkey T, Trinidad J, Kovalchin C, Minta A, Rosenbach M, Kaffenberger BH (2022) Defining drugs that are high-risk associations for drug reactions within the hospital setting. J Clin Aesthetic Dermatol 15(6):59

    Google Scholar 

  17. Krueger J, Puig L, Thaçi D (2022) Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol 1–14.

  18. Gooderham MJ, Van Voorhees AS, Lebwohl MG (2019) An update on generalized pustular psoriasis. Expert Rev Clin Immunol 15(9):907–919

    Article  CAS  PubMed  Google Scholar 

  19. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, Doshi JA (2015) Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Investigative Dermatol 135(12):2955–2963

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Claire Kovalchin is supported by the Bennett Student Research Fund at The Ohio State University.

Dr. Benjamin Kaffenberger is an investigator for AnaptysBio, Biogen, InflaRx, OnQuality Pharmaceuticals and the Dermatology Foundation.

Author information

Authors and Affiliations

  1. The Ohio State University College of Medicine, Columbus, OH, USA

    Claire E. Kovalchin, Ty W. Gilkey & Abena Minta

  2. Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 2012 Kenny Road, Columbus, OH, 43221, USA

    Jessica Kaffenberger, John Trinidad & Benjamin H. Kaffenberger

  3. Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA

    Johann Gudjonsson

Authors
  1. Claire E. Kovalchin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Kaffenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Trinidad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ty W. Gilkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abena Minta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Johann Gudjonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Benjamin H. Kaffenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BK developed the study design and provided oversight and assistance with data analysis and manuscript composition. CK assisted with study design, performed data analysis, and wrote the manuscript. TG created the database used for the study. TG, AM, JG, JK, and JT provided input on study design and data interpretation. All authors provided revisions on the manuscript and approved the final manuscript.

Corresponding author

Correspondence to Benjamin H. Kaffenberger.

Ethics declarations

Competing interests

Dr. Benjamin Kaffenberger is an investigator for AnaptysBio, Biogen, InflaRx, OnQuality Pharmaceuticals and the Dermatology Foundation

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kovalchin, C.E., Kaffenberger, J., Trinidad, J. et al. Characterizing risk factors for hospitalization for psoriasis patients. Arch Dermatol Res 315, 1541–1546 (2023). https://doi.org/10.1007/s00403-023-02533-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-023-02533-5

Keywords

Search

Navigation